TY - JOUR
T1 - Immunological mechanisms of the antitumor effects of supplemental oxygenation
AU - Hatfield, Stephen M.
AU - Kjaergaard, Jorgen
AU - Lukashev, Dmitriy
AU - Schreiber, Taylor H.
AU - Belikoff, Bryan
AU - Abbott, Robert
AU - Sethumadhavan, Shalini
AU - Philbrook, Phaethon
AU - Ko, Kami
AU - Cannici, Ryan
AU - Thayer, Molly
AU - Rodig, Scott
AU - Kutok, Jeffrey L.
AU - Jackson, Edwin K.
AU - Karger, Barry
AU - Podack, Eckhard R.
AU - Ohta, Akio
AU - Sitkovsky, Michail V.
N1 - Publisher Copyright:
© 2015 American Association for the Advancement of Science.
PY - 2015/3/4
Y1 - 2015/3/4
N2 - Antitumor T cells either avoid or are inhibited in hypoxic and extracellular adenosine-rich tumor microenvironments (TMEs) by A2A adenosine receptors. This may limit further advances in cancer immunotherapy. There is a need for readily available and safe treatments that weaken the hypoxia-A2-adenosinergic immunosuppression in the TME. Recently, we reported that respiratory hyperoxia decreases intratumoral hypoxia and concentrations of extracellular adenosine. We show that it also reverses the hypoxia-adenosinergic immunosuppression in the TME. This, in turn, stimulates (i) enhanced intratumoral infiltration and reduced inhibition of endogenously developed or adoptively transfered tumor-reactive CD8 T cells, (ii) increased proinflammatory cytokines and decreased immunosuppressive molecules, such as transforming growth factor-β (TGF-β), (iii) weakened immunosuppression by regulatory T cells, and (iv) improved lung tumor regression and long-term survival in mice. Respiratory hyperoxia also promoted the regression of spontaneous metastasis from orthotopically grown breast tumors. These effects are entirely T cell-and natural killer cell-dependent, thereby justifying the testing of supplemental oxygen as an immunological coadjuvant to combine with existing immunotherapies for cancer.
AB - Antitumor T cells either avoid or are inhibited in hypoxic and extracellular adenosine-rich tumor microenvironments (TMEs) by A2A adenosine receptors. This may limit further advances in cancer immunotherapy. There is a need for readily available and safe treatments that weaken the hypoxia-A2-adenosinergic immunosuppression in the TME. Recently, we reported that respiratory hyperoxia decreases intratumoral hypoxia and concentrations of extracellular adenosine. We show that it also reverses the hypoxia-adenosinergic immunosuppression in the TME. This, in turn, stimulates (i) enhanced intratumoral infiltration and reduced inhibition of endogenously developed or adoptively transfered tumor-reactive CD8 T cells, (ii) increased proinflammatory cytokines and decreased immunosuppressive molecules, such as transforming growth factor-β (TGF-β), (iii) weakened immunosuppression by regulatory T cells, and (iv) improved lung tumor regression and long-term survival in mice. Respiratory hyperoxia also promoted the regression of spontaneous metastasis from orthotopically grown breast tumors. These effects are entirely T cell-and natural killer cell-dependent, thereby justifying the testing of supplemental oxygen as an immunological coadjuvant to combine with existing immunotherapies for cancer.
UR - http://www.scopus.com/inward/record.url?scp=84929008590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929008590&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aaa1260
DO - 10.1126/scitranslmed.aaa1260
M3 - Article
C2 - 25739764
AN - SCOPUS:84929008590
SN - 1946-6234
VL - 7
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 277
ER -